Drug intelligence / Profile preview

KURA-003

Development stage: Preclinical
Lead developer: Kures
Administration: Oral

Overview

KURA-003 is a preclinical-stage drug candidate being developed for the treatment of substance use disorders, including opioid use disorder (OUD) and alcohol use disorder (AUD). It was acquired by atai Life Sciences from Kures as part of atai's strategy to expand its pipeline in addiction disorders.

Beyond the preview

Go deeper on KURA-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KURA-003.

Explore the full profile